Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
Johns Hopkins Medical Institutions
Office of Communications and Public Affairs
Media Contact: Vanessa Wasta
October 4, 2004
LOW DOSE RADIATION EVADES CANCER CELLS' PROTECTIVE "RADAR"
Kills More Cells Than High-Dose Radiation
A new study shows that lower doses of radiation elude a damage detection "radar" in DNA and actually kill more cancer cells than high-dose radiation. With these findings, scientists believe they can design therapy to dismantle this "radar" sensor allowing more radiation to evade detection and destroy even greater numbers of cancer cells.
Researchers at the Johns Hopkins Kimmel Cancer Center tested the low-dose radiation strategy on cultured prostate and colon cancer cell lines and found that it killed up to twice as many cells as high-dose radiation. The extra lethality of the low-dose regimen was found to result from suppression of a protein, called ATM (ataxia telangiectasia mutated), which works like a radar to detect DNA damage and begin repair.
Theodore DeWeese, M.D., who led the study, speculates that cells hit with small amounts of radiation fail to switch on the ATM radar, which prevents an error-prone repair process. DeWeese, who will present his evidence at the annual meeting of the American Society for Therapeutic Radiology and Oncology on October 5 in Atlanta, explains.
"DNA repair is not foolproof -- it can lead to mistakes or mutations that are passed down to other generations of cells," explains DeWeese, chairman of the Department of Radiation Oncology and Molecular Radiation Sciences at Johns Hopkins. "A dead cell is better than a mutant cell, so if the damage is mild, cells die instead of risking repair."
Higher doses of radiation cause extreme DNA damage and widespread cell death, so the ATM damage sensor is activated to preserve as many cells as possible, protecting, ironically, the cancer cells under target for destruction by the radiation.
While the low-dose regimen works in cultured cells, it has not proved successful in humans. This has lead to effort by Johns Hopkins scientists to study ways to use viruses that can deliver ATM-blocking drugs to the cells. Tests in animals are expected to begin soon.
In the current study, colon and prostate cancer cells lines were treated with either high levels of radiation or small amounts spread over many days. Low-level radiation is approximately 10 times more powerful than normal exposure, while high doses are 1,000 times stronger. Approximately 35 percent of colon cancer cells survived low-dose radiation as compared to 60 percent receiving high-dose. In prostate cancer cell lines, half of the cells survived low-dose radiation, while 65 percent remained in higher doses.
In the low-dose group, ATM activation was reduced by 40 to 50 percent. The researchers proved ATM inactivation was the culprit since low-dose irradiated cells fared better after ATM was reactivated with chloroqine, best known as a treatment for malaria.
"Tricking cancer cells into ignoring the damage signals that appear on its radar could succeed in making radiation more effective in wiping out the disease," says DeWeese.
This research was funded by the National Cancer Institute.
Research participants from Johns Hopkins include Spencer Collis, Julie
Schwaninger, Alfred Ntambi, Thomas Keller, Larry Dillehay, and William Nelson.
Collis, S. et al, "Low-Level Radiation-Induced DNA Damage Evades Early Cellular Response Mechanisms Leading to Increased Cell Death," ASTRO Proceedings, Abstract #2012.
Johns Hopkins Department of Radiation Oncology and Molecular Radiation Sciences: www.radonc.jhmi.edu
Johns Hopkins Kimmel Cancer Center: www.hopkinskimmelcancercenter.org
- -JHMI- -